The Cytosponge enables testing in primary care for Barrettâ€™s oesophagus, a condition that can increase a personâ€™s risk of developing oesophageal cancer. A big challenge with this type of cancer is that many people donâ€™t realise thereâ€™s a problem until they start to have trouble swallowing. Often, these symptoms arenâ€™t recognisable until a later stage in the disease.
Created byÂ Cyted, itâ€™s a cheap and simple test that can be done in a GP surgery instead of a referral to hospital for an endoscopy.
Following a proposal supported by Eastern AHSN, the government has announced a 3.5 million funding boost to trial the use of the Cytosponge TFF3 testÂ to diagnose Barrettâ€™s oesophagus in patients with symptoms such as heartburn in primary and secondary care settings.
CytospongeÂ is a small coated pill on a string that contains the sponge. Itâ€™s easy for people to swallow, and when the pill reaches the stomach, the coating dissolves and the sponge expands. The sponge collects cells from the lining of the oesophagus as it is pulled back up and is then sent for analysis, where pathologists will use a simple antibody test to spot the signs of the patient being precancerous.
Cyted is enabling the earlier detection of disease, providing products and services that combine proprietary artificial intelligence technology and digital diagnostic infrastructure with next generation biomarkers.
Do you have a great idea that could make a positive health impact?Get involved